The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|September 28, 2022
Alcami Adds Solid-State Characterization Capabilities to North Carolina Laboratory
Author(s)Pharmaceutical Technology Editors
The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.
Advertisement
Alcami, a US-based pharmaceutical contract development and manufacturing organization (CDMO), announced the addition of a 12,000 ft² solid-state characterization laboratory to its Morrisville, NC laboratory on Sept. 22, 2022. According to a company press release, the expanded laboratory is designed to increase the company’s NC footprint and complement the company’s existing sterile and oral solid drug product development, manufacturing, and analytical capabilities for products in all phases of development.
"We look forward to supporting our clients in the discovery of novel polymorph, salt, and cocrystal forms and in the development of robust crystallization and formulation processes," said Elliott Franco, vice-president, Laboratory Operations, Alcami, in the press release. "We have the technical expertise and technologies to provide our clients with a seamless transition from initial characterization through [good manufacturing practice] manufacturing and analytical release.”
Source:
Advertisement
Related to this article
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
5